Neuro-oncology Management During the COVID-19 Pandemic With a Focus on WHO Grade III and IV Gliomas

In this consensus statement recently published in Neuro-Oncology, an international group of experts present mitigation strategies and treatment guidance for patients suffering from high grade gliomas (HGG) during the COVID-19 pandemic.

In this consensus statement recently published in Neuro-Oncology, an international group of experts present mitigation strategies and treatment guidance for patients suffering from high grade gliomas (HGG) during the COVID-19 pandemic. 16 international experts in the treatment of HGG contributed including neuro-oncologists, neurosurgeons, radiation-oncologists and a medical physicist. Generally, treatment of neuro-oncological patients cannot be significantly delayed and initiating therapy should not be outweighed by COVID-19. Moreover, the authors present detailed interdisciplinary treatment strategies for molecular subgroup in two pandemic scenarios, a scale-up phase and a crisis phase.
https://academic.oup.com/neuro-oncology/advance-article/doi/10.1093/neuonc/noaa113/5829911

by Marialuisa Zedde and Francesco Cavallieri